Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $731.1 million.

  • Krystal Biotech's Cash & Current Investments rose 2426.3% to $731.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.1 million, marking a year-over-year increase of 2426.3%. This contributed to the annual value of $597.5 million for FY2024, which is 1227.77% up from last year.
  • Krystal Biotech's Cash & Current Investments amounted to $731.1 million in Q3 2025, which was up 2426.3% from $682.0 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Cash & Current Investments registered a high of $731.1 million during Q3 2025, and its lowest value of $343.1 million during Q3 2021.
  • Moreover, its 5-year median value for Cash & Current Investments was $477.5 million (2023), whereas its average is $495.9 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 1938.31% in 2023, then skyrocketed by 5361.84% in 2024.
  • Krystal Biotech's Cash & Current Investments (Quarter) stood at $438.1 million in 2021, then dropped by 13.45% to $379.2 million in 2022, then surged by 40.35% to $532.2 million in 2023, then grew by 12.28% to $597.5 million in 2024, then grew by 22.35% to $731.1 million in 2025.
  • Its last three reported values are $731.1 million in Q3 2025, $682.0 million for Q2 2025, and $616.8 million during Q1 2025.